Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
No. 5 Pixu decoction is a traditional Chinese medicine (TCM) formulation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences for the treatment of functional diarrhea. It is specifically designed to address the TCM syndrome of 'Spleen Deficiency' (Pixu), a common diagnostic pattern in gastrointestinal disorders. The decoction was evaluated in a multicenter, randomized, double-blind, placebo-controlled clinical trial (ChiCTR-TRC-13003202) to determine its efficacy and safety in patients diagnosed with functional diarrhea according to Rome III criteria. As a 'differential treatment' formulation, it is typically used alongside or compared with other Pixu-targeting decoctions (such as No. 4 Pixu decoction) to tailor therapy to specific patient presentations within the spleen deficiency spectrum.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on No. 5 Pixu decoction.